São Paulo - Delayed Quote • BRL GSK plc (G1SK34.SA) Follow Compare 40.94 0.00 (0.00%) As of January 28 at 12:44:16 PM GMT-3. Market Open. Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for G1SK34.SA 1D 5D 1.99% 1M -2.43% 3M -6.87% 6M -9.32% YTD -1.49% 1Y 6.09% 5Y -20.79% All -20.79% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: G1SK34.SA View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline GSK announces EMA accepted for review the MAA for depemokimab The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings GSK and Oxford researchers to create cancer vaccine to stop disease developing Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer Is GSK plc (GSK) an Undervalued Defensive Stock for 2025? Ozempic, Xtandi among next 15 drugs selected for U.S. price talks Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations Is GSK plc (GSK) One of the Cheapest Stocks with Biggest Upside Potential? Healthcare M&A poised for a rebound in 2025